Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Rhea-AI Summary

Dr. Reddy's Laboratories announced the acquisition of Haleon's Nicotinell and related NRT brands for GBP 500 million. The acquisition includes Nicotinell's global portfolio, comprising Nicabate, Thrive, and Habitrol, across Europe, Asia, and Latin America. The deal features an upfront payment of GBP 458 million and performance-based payments of up to GBP 42 million. Nicotinell, the second-largest NRT brand globally, generated GBP 217 million in revenue in CY'23. Dr. Reddy's aims to expand its OTC business and strengthen its global consumer healthcare presence. The transaction is expected to close in early Q4 2024.

Positive

• Dr. Reddy's acquisition of Nicotinell and related brands enhances its global OTC presence.
• The deal, valued at GBP 500 million, includes a strong portfolio with GBP 217 million in CY'23 revenue.
• Nicotinell is the second-largest global NRT brand, holding top positions in key markets.
• The acquisition offers strategic expansion in Europe, Asia, and Latin America.
• Dr. Reddy's will gain access to over 30 countries' NRT markets and various product formats.

Negative

• The acquisition involves a significant upfront cash payment of GBP 458 million.
• Performance-based payments of up to GBP 42 million add future financial obligations.

Financial Analyst

Dr. Reddy’s acquisition of Nicotinell and its related portfolio for GBP 500 million is a notable strategic move that will significantly bolster its global consumer healthcare business, especially in the over-the-counter (OTC) segment. This acquisition will provide Dr. Reddy’s with a solid revenue stream, considering that the portfolio generated approximately GBP 217 million in revenue in CY’23. From a financial perspective, this acquisition appears to be a sound investment, given Nicotinell's leading market positions in 14 of the top 17 global markets in the Nicotine Replacement Therapy (NRT) category.

Additionally, the upfront cash payment of GBP 458 million with performance-based contingent payments of up to GBP 42 million in 2025 and 2026 indicates a structured financial plan with a focus on future growth and performance. The integration strategy, which involves a phased transition of operations to Dr. Reddy’s, is a prudent approach that minimizes the risk of disruption and ensures a smooth incorporation of the new assets into its existing business framework.

For retail investors, this deal suggests potential for enhanced earnings and shareholder value in the long term, reflecting positively on Dr. Reddy’s commitment to expanding its consumer healthcare footprint globally.

Market Research Analyst

From a market research perspective, the acquisition of Nicotinell and its related brands positions Dr. Reddy’s strongly within the global NRT market. Nicotinell’s leadership in various markets and its presence in over 30 countries provides Dr. Reddy’s with a vast and diverse consumer base. The portfolio’s extensive product formats, including lozenge, patch and gum, cater to different consumer preferences, making it a versatile addition to Dr. Reddy’s OTC offerings.

The strategic move also aligns well with the global trend towards healthier lifestyles and increasing efforts to combat tobacco addiction. With the World Health Organization highlighting a significant demand for cessation tools, the acquisition is timely and could leverage this growing demand. Moreover, the portfolio’s strong brand recognition and customer loyalty, coupled with Dr. Reddy’s robust marketing and digital capabilities, could unlock further market potential and drive growth.

Retail investors should note that this acquisition not only strengthens Dr. Reddy’s market share in the NRT segment but also enhances its brand equity and competitive edge in the broader consumer healthcare market.

Healthcare Industry Expert

In the healthcare industry context, Dr. Reddy’s acquisition of Nicotinell and its related portfolio is a substantial move that underscores the company’s commitment to expanding its consumer healthcare business. Nicotinell’s prominence as a leading NRT brand fits well with global health initiatives aimed at reducing tobacco use and its associated health risks. This acquisition aligns with the World Health Organization’s recommendation of NRT as an essential treatment for nicotine use disorders, which could enhance Dr. Reddy’s position as a provider of essential health solutions.

The diverse product formats and established market presence of Nicotinell and its related brands, such as Nicabate, Thrive and Habitrol, will enable Dr. Reddy’s to offer a comprehensive range of cessation tools across various geographies. This acquisition not only broadens Dr. Reddy’s product portfolio but also reinforces its role in public health by providing accessible and effective treatments for nicotine dependence.

Investors should consider the long-term health impact and the potential for ongoing revenue generation from a health-focused product line that addresses a significant global health challenge.

• Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States
• Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC business
• In recent years, Dr. Reddy’s has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé India

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced that its subsidiary Dr. Reddy's Laboratories SA has signed a definitive agreement with Haleon plc (LSE/NYSE: HLN; “Haleon”), a leading consumer healthcare company, for purchase of shares of Northstar Switzerland SARL, a Haleon group company, to acquire Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (“NRT”) category outside of the United States. The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.

Dr. Reddy’s to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business (Graphic: Business Wire)

Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category. It holds the first or second position in 14 of the top 17 global markets, with the lozenge/mini lozenge format holding top position globally¹. Nicotinell ranks among the top 15 biggest brands among all OTC brands in Europe (excluding Russia, Italy), and ranks 32 among all OTC global brands (excluding the U.S.)². In CY’23, the portfolio generated approximately GBP 217 million in revenue.

Dr. Reddy’s will acquire the share capital of Northstar Switzerland SARL for a total consideration of GBP 500 million with an upfront cash payment of GBP 458 million and performance-based contingent payments of up to GBP 42 million, payable in 2025 and 2026. The closing of the transaction is subject to satisfactory completion of customary conditions to closing, including regulatory approvals. The transaction is expected to close in early Q4 of calendar year 2024.

Upon closing of the transaction, Dr. Reddy’s will acquire the NRT business in all countries outside of the United States. However, operations will transition to Dr. Reddy’s in a phased approach to ensure successful integration of the business.

Tobacco use causes eight million deaths every year from health consequences such as cardiovascular diseases, lung disorders, cancers, diabetes, and many other debilitating diseases. According to the World Health Organization (“WHO”), of the 1.3 billion tobacco users globally, as many as 60% have expressed the desire to quit; however only 30% have access to the tools to help them to do so successfully. Safe and effective medical treatments to help individuals quit tobacco are available, but not always sufficiently available or accessible³.

NRT is recommended by the ‘World Health Organization Model List of Essential Medicines’ for nicotine use disorders⁴. NRT also played a key role in the WHO’s ‘Access Initiative for Quitting Tobacco’ launched in 2020 to help tobacco users quit to reduce the risk of severe outcomes from COVID-19 infection⁵.

In line with its stated strategic intention, Dr. Reddy’s continues to focus on its core business of generics, branded generics, Active Pharmaceutical Ingredients (API), over-the-counter (OTC) products, and biosimilars. Alongside this, the company has been investing in growth drivers of the future in three areas – access to novel molecules (NCEs, NBEs, CAR-T); digital therapeutics (wearables, apps); and consumer healthcare (including nutrition and OTC wellness products). As part of its consumer healthcare OTC business in the United States, Dr. Reddy’s has in recent years acquired several well-known brands such as the NRT brand Habitrol®, pain-relief brand Doan’s®, women’s health products such as Premama® for fertility and parenthood, and the MenoLabs® portfolio for menopause. In India, Dr. Reddy’s has a portfolio of OTC products in the hydration, cough-cold-allergy, and skin care categories. The recent announcement of a joint venture with Nestlé India to bring the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) to India, is another significant move to strengthen its nutrition and OTC business in India. In Emerging Markets, Dr. Reddy’s has a long-established and sizeable OTC business with market-leading products in the allergy, pain relief, gastro-intestinal and women’s health categories in Russia & CIS, South Africa, Asia, Latin America & the Caribbean. Earlier this year, Dr. Reddy’s entered the UK consumer health market with the launch of the allergy medication Histallay. With increasing presence in consumer health and OTC in global markets, the company has been strengthening its capabilities in brand-building, marketing, digital and analytics, including exploring e-commerce partnerships. The latest proposed acquisition of Nicotinell and related portfolio gives Dr. Reddy’s a strong footprint in Europe as well as other global markets, complementing and building on its existing global presence and capabilities.

Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We see the acquisition of this global portfolio of consumer healthcare products led by the global brand Nicotinell as a logical extension of our efforts in consumer healthcare OTC in recent years, and of our purpose of ‘Good Health Can’t Wait’. We have been steadily building our OTC presence in various markets and investing in our capabilities. As a business, consumer healthcare is a growing and sustainable business with favourable long-term trends. The business to be acquired from Haleon has maintained steady sales and strong profitability over the years. The portfolio is attractive for its customer loyalty, its global nature, and the access it provides to key customers. We believe we can unlock more value, grow the portfolio further, and increase consumer access around the world to these global brands. Given these advantages, it is the ideal anchor around which to build a larger global OTC platform.”

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

About Haleon: Haleon (LSE /NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum – are built on trusted science, innovation and deep human understanding. For more information, please visit www.haleon.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.

^{______________________
1} Based on 2022 Retail Sales Value
² Nicholas Hall DB6 database 2023 (definition of global brands – sold in at least 5 countries / 2 regions)
³ https://www.who.int/news/item/05-11-2021-two-new-tobacco-cessation-medicines-added-to-the-who-essential-medicines-list#:~:text=On%201%20October%202021%2C%20the,wish%20to%20stop%20using%20tobacco.
⁴ WHO Model List of Essential Medicines 2023 - https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
⁵ https://www.who.int/news/item/10-07-2020-who-and-partners-to-help-more-than-1-billion-people-quit-tobacco-to-reduce-risk-of-covid-19#:~:text=The%20project%20gives%20people%20free,personalized%20plan%20to%20quit%20tobacco.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626898799/en/

INVESTOR RELATIONS

RICHA PERIWAL

richaperiwal@drreddys.com



MEDIA RELATIONS

USHA IYER

USHAIYER@DRREDDYS.COM

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What significant acquisition did Dr. Reddy's Laboratories announce?

Dr. Reddy's Laboratories announced the acquisition of Haleon's Nicotinell and related NRT brands for GBP 500 million.

What brands are included in Dr. Reddy's acquisition of Haleon's portfolio?

The acquisition includes Nicotinell's global portfolio, comprising Nicabate, Thrive, and Habitrol.

How much revenue did Nicotinell generate in CY'23?

Nicotinell generated approximately GBP 217 million in revenue in CY'23.

What is the total value of the acquisition deal involving Dr. Reddy's and Haleon?

The total value of the acquisition deal is GBP 500 million.

How will Dr. Reddy's finance the acquisition of Haleon's portfolio?

Dr. Reddy's will make an upfront cash payment of GBP 458 million and performance-based contingent payments of up to GBP 42 million.

When is the acquisition deal between Dr. Reddy's and Haleon expected to close?

The transaction is expected to close in early Q4 2024.

What strategic benefits will Dr. Reddy's gain from acquiring Nicotinell and related brands?

The acquisition will enhance Dr. Reddy's global OTC presence, expand its market reach in Europe, Asia, and Latin America, and strengthen its consumer healthcare business.